(FT) Big pharma’s billion-dollar bets

Why is big pharma paying billions to take over small companies? Arash Massoudi, the FT’s corporate finance and deals editor, explains that as patents expire and the pressure to cut R&D costs rises, large pharmaceutical companies are being forced to make risky bets in search of the next blockbuster drug.